耐药时代下抗菌肽的价值
本文综述了抗菌肽作为应对多重耐药病原体新型治疗药物的优势、挑战与机遇。抗菌肽具有耐药性产生较慢、广谱抗生物膜活性及调节宿主免疫反应等优点,但结构功能局限和严格监管阻碍了临床转化。现有计算与实验工具可助力其临床前及临床开发。
要点
- 抗菌肽耐药性产生较慢且具广谱抗生物膜活性。
- 抗菌肽可有利调节宿主免疫反应。
- 结构功能局限与严格监管阻碍临床转化。
核心结论
- 抗菌肽是应对多重耐药病原体的潜在新型治疗药物,但临床转化受限于结构功能局限和严格监管。
研究设计与样本
- 本文为综述,检索范围未在摘要中报告。
主要发现
- 抗菌肽相比传统抗生素具有耐药性产生较慢、广谱抗生物膜活性和有利调节宿主免疫反应的优势。
- 细菌对抗菌肽的广泛敏感性为扩展抗菌药物耐药进化知识提供了额外工具。
- 现有计算与实验工具试图促进抗菌肽作为新疗法的临床前和临床开发。
临床怎么用
- 临床可关注抗菌肽作为多重耐药病原体治疗选择的潜力,但需注意其临床转化尚不成熟。
局限性
- 结构功能局限和更严格的监管环境阻碍了抗菌肽的临床转化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Accelerating growth and global expansion of antimicrobial resistance has deepened the need for discovery of novel antimicrobial agents. Antimicrobial peptides have clear advantages over conventional antibiotics which include slower emergence of resistance, broad-spectrum antibiofilm activity, and the ability to favourably modulate the host immune response. Broad bacterial susceptibility to antimicrobial peptides offers an additional tool to expand knowledge about the evolution of antimicrobial resistance. Structural and functional limitations, combined with a stricter regulatory environment, have hampered the clinical translation of antimicrobial peptides as potential therapeutic agents. Existing computational and experimental tools attempt to ease the preclinical and clinical development of antimicrobial peptides as novel therapeutics. This Review identifies the benefits, challenges, and opportunities of using antimicrobial peptides against multidrug-resistant pathogens, highlights advances in the deployment of novel promising antimicrobial peptides, and underlines the needs and priorities in designing focused development strategies taking into account the most advanced tools available.
引用
- Magana M, Pushpanathan M, Santos AL, et al. The value of antimicrobial peptides in the age of resistance. Lancet Infect Dis. 2020. PMID: 32653070. doi:10.1016/S1473-3099(20)30327-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。